How Repeal of the NTAP Alternative Pathway will Impact U.S. Clinical AI Innovation
NEJM AI · 24.09.2026 · 3 (10)
DOI: 10.1056/aipc2600711 ↗Kurz gefasst
Editorial in der Zeitschrift NEJM AI, erschienen am 24.09.2026. Verfasst von Andrew Wong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA. Hauptthemen laut MEDLINE: Artificial Intelligence, Reimbursement Mechanisms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
- Department of Biomedical Informatics, University of Utah, Salt Lake City, UT, USA.
- Division of Clinical Informatics and Digital Transformation, University of California, San Francisco, CA, USA.
- University of Michigan Law School, Ann Arbor, MI, USA.
- Department of Learning Health Sciences, University of Michigan, Ann Arbor, MI, USA.
- Joan and Irwin Jacobs Center for Health Innovation, UC San Diego Health, San Diego, CA, USA.
ORCID-Profile: Andrew Wong, Julia Adler-Milstein, W Nicholson Price, Karandeep Singh
Zitieren
APA
Wong, A., Adler-Milstein, J., Nicholson Price, W., & Singh, K. (2026). How Repeal of the NTAP Alternative Pathway will Impact U.S. Clinical AI Innovation. NEJM AI, 3(10). https://doi.org/10.1056/aipc2600711
Vancouver
Wong A, Adler-Milstein J, Nicholson Price W, Singh K. How Repeal of the NTAP Alternative Pathway will Impact U.S. Clinical AI Innovation. NEJM AI. 2026;3(10). doi:10.1056/aipc2600711
BibTeX
@article{Wong2026,
author = {Wong, Andrew and Adler-Milstein, Julia and Nicholson Price, W and Singh, Karandeep},
title = {How Repeal of the NTAP Alternative Pathway will Impact U.S. Clinical AI Innovation},
journal = {NEJM AI},
year = {2026},
volume = {3},
number = {10},
doi = {10.1056/aipc2600711}
}
EUVIMED